169
MBA 5–3
1. Year 3 Year 2 Year 1
Monthly cash expenses:
$212,889 (in thousands) ÷ 12 ……. $17,741
$129,753 (in thousands) ÷ 12 ……. $10,813
$100,989 (in thousands) ÷ 12 ……. $8,416
2. Ratio of cash to monthly
cash expenses:
3. Ratio of cash to monthly
cash expenses:
($136,986 + $0) ÷ $17,741 ………….. 7.7 months
($82,387 + $0) ÷ $10,813 ……………. 7.6 months
($61,653 + $50,097) ÷ $8,416 ……… 13.3 months
4. Synergy Pharmaceuticals has reported losses and negative cash flows from
operations in each of the three years analyzed. Synergy Pharmaceuticals was
able to raise funds by issuing stock in all three years and issuing long-term
debt in Year 3. At the end of Year 1, with negative monthly cash flows of
5. Based upon the preceding results in (2) and (3), loaning money to Synergy
Pharmaceuticals would be extremely risky. Unless management of Synergy
could convince you that a turnaround was likely and that Synergy would gen-